Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE‐012

KEYNOTE‐012 was a phase Ib, multicohort study designed to investigate efficacy and safety of pembrolizumab in advanced solid tumors. Results from the subset of patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) from the Asia‐Pacific region are reported. Patients with re...

Descripción completa

Detalles Bibliográficos
Autores principales: Tahara, Makoto, Muro, Kei, Hasegawa, Yasuhisa, Chung, Hyun Cheol, Lin, Chia‐Chi, Keam, Bhumsuk, Takahashi, Kenichi, Cheng, Jonathan D., Bang, Yung‐Jue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834807/
https://www.ncbi.nlm.nih.gov/pubmed/29284202
http://dx.doi.org/10.1111/cas.13480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834807/
https://www.ncbi.nlm.nih.gov/pubmed/29284202
http://dx.doi.org/10.1111/cas.13480

Ejemplares similares